Literature DB >> 15947328

Bronchoscopy-guided topical hemostatic tamponade therapy for the management of life-threatening hemoptysis.

Arschang Valipour1, Alois Kreuzer, Hubert Koller, Wolfgang Koessler, Otto Chris Burghuber.   

Abstract

STUDY
OBJECTIVES: Massive hemoptysis is a life-threatening condition. Therapeutic strategies such as interventional angiography, surgery, and/or bronchoscopy have been applied in the clinical setting with variable results. We investigated the efficacy of bronchoscopy-guided topical hemostatic tamponade therapy (THT) using oxidized regenerated cellulose (ORC) mesh in the management of life-threatening hemoptysis.
DESIGN: Seventy-six consecutive patients underwent emergency bronchoscopy for massive hemoptysis. Fifty-seven patients (75%) had persistent endobronchial bleeding despite bronchoscopic wedging technique, cold saline solution lavage, and instillation of regional vasoconstrictors. These patients subsequently underwent THT according to the same procedure.
SETTING: Teaching hospital, bronchoscopy unit of a 300-bed tertiary pulmonary referral center.
RESULTS: THT with ORC was successfully performed on 56 of 57 patients (98%) with an immediate arrest of hemoptysis. All patients successfully treated with THT remained free of hemoptysis for the first 48 h. None required intensive care support or immediate surgery. Mean procedure time (+/- SD) of THT was 11.5 +/- 4.2 min. Recurrence of hemoptysis that was characterized as being mild (< 30 mL) to moderate (30 to 100 mL) developed in six patients (10.5%) 3 to 6 days after THT. Post-obstructive pneumonia developed in five subjects (9%) after endoscopic THT. A subgroup of patients (n = 14) underwent bronchoscopic follow-up 4 weeks after discharge. The ORC mesh was absorbed in all of these patients without signs of foreign body reaction.
CONCLUSIONS: Endobronchial THT using ORC is a safe and practicable technique in the management of life-threatening hemoptysis with a high success and a relatively low complication rate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947328     DOI: 10.1378/chest.127.6.2113

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

Review 1.  Lung Cancer OncoGuia.

Authors:  Paula Manchon Walsh; Paula Manchon; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2009-12       Impact factor: 3.405

Review 2.  [Endoscopic interventions in pulmonology].

Authors:  D Gompelmann; F J F Herth
Journal:  Internist (Berl)       Date:  2016-08       Impact factor: 0.743

Review 3.  A systematic approach to the management of massive hemoptysis.

Authors:  Christopher Radchenko; Abdul Hamid Alraiyes; Samira Shojaee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 4.  Palliative care in lung cancer.

Authors:  Betty Ferrell; Marianna Koczywas; Fred Grannis; Annie Harrington
Journal:  Surg Clin North Am       Date:  2011-04       Impact factor: 2.741

5.  Novel Bronchoscopic Management of Airway Bleeding With Absorbable Gelatin and Thrombin Slurry.

Authors:  A Rolando Peralta; Mohit Chawla; Robert P Lee
Journal:  J Bronchology Interv Pulmonol       Date:  2018-07

6.  Induced airway obstruction under extracorporeal membrane oxygenation during treatment of life-threatening massive hemoptysis due to severe blunt chest trauma.

Authors:  Jong Myung Park; Chang Wan Kim; Hyun Min Cho; Bong Soo Son; Do Hyung Kim
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

7.  Management of patients presenting with haemoptysis to a Tertiary Care Italian Emergency Department: the Florence Haemoptysis Score (FLHASc).

Authors:  Simone Vanni; Simone Bianchi; Sofia Bigiarini; Claudia Casula; Marco Brogi; Stefano Orsi; Manlio Acquafresca; Lorenzo Corbetta; Stefano Grifoni
Journal:  Intern Emerg Med       Date:  2017-02-03       Impact factor: 3.397

8.  [Emergencies in adult mucoviscidosis patients].

Authors:  C Smaczny; T Born; T O F Wagner
Journal:  Internist (Berl)       Date:  2012-05       Impact factor: 0.743

Review 9.  Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

Authors:  M Reck; F Barlesi; L Crinò; C I Henschke; D Isla; S Stiebeler; D R Spigel
Journal:  Ann Oncol       Date:  2011-11-04       Impact factor: 32.976

10.  An integrated approach to diagnosis and management of severe haemoptysis in patients admitted to the intensive care unit: a case series from a referral centre.

Authors:  Muriel Fartoukh; Antoine Khalil; Laurence Louis; Marie-France Carette; Bernard Bazelly; Jacques Cadranel; Charles Mayaud; Antoine Parrot
Journal:  Respir Res       Date:  2007-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.